Alger Small Cap Focus Fund Q3 2026 Portfolio Update

Forte Biosciences, Twist Bioscience, and Adaptive Biotechnologies were among the quarter’s top performance contributors, while Cardinal Infrastructure Group, RBC Bearings, and VSE Corporation were among the top detractors. VSE detracted despite strong revenue growth, record profitability, and an improved full-year outlook; the article provides no performance figures.

Analysis

The main signal is a disconnect between reported operating momentum and shareholder returns at VSE (VSEC): a stronger outlook did not prevent quarterly underperformance. That raises an expectations/valuation question, not by itself evidence that fundamentals are deteriorating. The next test is whether results convert into durable organic growth and cash generation; verify backlog, segment growth, margins, free-cash-flow conversion, and any balance-sheet or acquisition-related constraints before treating the weakness as an entry point.

The contributor/detractor list is relative-performance attribution, not a forward catalyst. With no return magnitudes, benchmark, valuation, or company-specific operating detail for FBRX, TWST, ADPT, CDNL, or RBC, their attribution should not be extrapolated into earnings momentum. In particular, do not infer that biotech contributors share a common driver or that CDNL/RBC underperformance signals deteriorating fundamentals.

Near term, attribution reversals or positioning may dominate. Over 1–3 months, earnings revisions and guidance quality can validate or negate the VSEC disconnect. Over 6–18 months, sustained cash conversion and margin durability matter more than a single quarter’s growth. A key contrarian possibility is that the market is discounting lower-quality or less repeatable growth; the opposite is that operational delivery is improving faster than valuation implies. Available evidence cannot distinguish these cases.

Key Decisions for Investors

• No immediate directional trade from this attribution alone. For VSEC, put the shares on an event watchlist and review the next earnings release for organic growth, margin progression, cash conversion, and guidance follow-through.
• Consider a conditional long VSEC only if operating delivery persists and cash conversion confirms earnings quality; falsify the thesis if guidance is cut, organic growth weakens materially, or margins/cash conversion deteriorate.
• Do not chase FBRX, TWST, or ADPT based solely on contributor status, or short CDNL/RBC based solely on detractor status. First verify attribution magnitude and period, valuation, relevant operating catalysts, and revisions versus expectations.
• Before taking a relative-value position, compare VSEC with relevant aerospace/aftermarket peers and RBC on valuation, growth quality, and revisions. The article provides no basis to size a pair trade or quantify risk/reward.